» Articles » PMID: 3026083

Prostate-specific Acid Phosphatase in Carcinoid Tumors

Overview
Date 1986 Jan 1
PMID 3026083
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Although prostate-specific acid phosphatase (PASP) has been recognized as a specific marker of tissue of prostatic origin, several investigators have pointed out that some of the carcinoid tumours and islet cell tumours of the pancreas reacted immunohistochemically to PSAP. We investigated 50 cases immunohistochemically comprising 44 carcinoids of the G-I tract, 3 of the bronchus, 1 each of the ovary, kidney and middle ear. PSAP positive cases were, 30 in G-I tract, one each in ovary and kidney. Eighty percent of tumours of hindgut origin were positive. Apart from the immunohistochemical study, the content of PSAP in preoperative serum and tumour tissue was estimated in a case with a rectal carcinoid. Extremely elevated PSAP was confirmed in both the serum and tumour tissue. Neuroendocrine tumours such as pheochromocytoma, medullary thyroid carcinoma, and islet cell carcinoma were investigated as controls. No cells immunoreactive to PSAP were observed in these control cases. Prostate specific antigen was definitely negative in carcinoids. We would emphasize that PSAP may be an excellent marker of carcinoids especially when derived from hindgut.

Citing Articles

Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues.

Tribian L, Lennartz M, Hoflmayer D, De Wispelaere N, Rico S, von Bargen C Diagnostics (Basel). 2023; 13(20).

PMID: 37892063 PMC: 10606209. DOI: 10.3390/diagnostics13203242.


Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.

He M, Zhang D, Cao Y, Chi C, Zeng Z, Yang X Heliyon. 2023; 9(8):e19147.

PMID: 37664750 PMC: 10469587. DOI: 10.1016/j.heliyon.2023.e19147.


Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease.

Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A Front Endocrinol (Lausanne). 2021; 12:709256.

PMID: 34690926 PMC: 8527170. DOI: 10.3389/fendo.2021.709256.


American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies.

Bellizzi A, Montgomery E, Hornick J Ann Diagn Pathol. 2019; 44:151419.

PMID: 31786484 PMC: 7681915. DOI: 10.1016/j.anndiagpath.2019.151419.


Pathology of Neuroendocrine Tumours of the Female Genital Tract.

Howitt B, Kelly P, McCluggage W Curr Oncol Rep. 2017; 19(9):59.

PMID: 28735441 DOI: 10.1007/s11912-017-0617-2.


References
1.
Li C, Lam W, Yam L . Immunohistochemical diagnosis of prostatic cancer with metastasis. Cancer. 1980; 46(4):706-12. DOI: 10.1002/1097-0142(19800815)46:4<706::aid-cncr2820460412>3.0.co;2-e. View

2.
AZZOPARDI J, Evans D . Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol. 1971; 104(4):247-51. DOI: 10.1002/path.1711040406. View

3.
Hsu S, RAINE L, FANGER H . Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-80. DOI: 10.1177/29.4.6166661. View

4.
Fishleder A, Tubbs R, Levin H . An immunoperoxidase technique to aid in the differential diagnosis of prostatic carcinoma. Cleve Clin Q. 1981; 48(3):331-5. DOI: 10.3949/ccjm.48.3.331. View

5.
OConnor D, Burton D, Deftos L . Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab. 1983; 57(5):1084-6. DOI: 10.1210/jcem-57-5-1084. View